Stopping itching

Stopping itching, clinically defined as the management of pruritus, refers to the pharmacological or physiological inhibition of the itch sensation. It is not a single molecular target but rather a therapeutic objective involving the modulation of complex neural and immunological pathways (Yosipovitch & Bernhard, 2013, NEJM). Pruritus is mediated by both histaminergic and non-histaminergic fibers, involving key molecular players such as the Histamine H1 receptor, Mas-related G-protein coupled receptors (MRGPRs), and protease-activated receptors (PAR2) (Dong & Dong, 2018, Neuron). Additionally, cytokines like IL-31 and IL-13 play critical roles in pruritus associated with inflammatory skin diseases by activating neuronal receptors that signal through the JAK-STAT pathway (Kim et al., 2021, JACI). Therapeutic strategies to stop itching vary by the underlying condition, ranging from traditional antihistamines for urticaria to modern biologics and small molecules for chronic inflammatory itch. For example, monoclonal antibodies like nemolizumab target the IL-31 receptor, while drugs like difelikefalin act as peripheral kappa-opioid receptor agonists to treat uremic pruritus (Misery et al., 2014, Nat Rev Neurol). Because 'Stopping itching' describes a physiological outcome rather than a specific protein or enzyme, it represents a clinical endpoint achieved by targeting various receptors and signaling cascades within the skin and nervous system.

Other names

Pruritus reliefAntipruritic effectItch suppressionManagement of pruritus

The suppression of itching is achieved through various molecular mechanisms depending on the etiology, including Histamine H1 receptor antagonism, Kappa-opioid receptor (KOR) agonism, Mu-opioid receptor (MOR) antagonism, Neurokinin-1 (NK1) receptor antagonism, Interleukin-31 receptor (IL-31R) blockade, and Janus kinase (JAK) inhibition (Yosipovitch & Bernhard, 2013, NEJM; Dong & Dong, 2018, Neuron).